The problems could cost the equivalent of US$57 billion, around 22 per cent of the total national health budget.

From US tariff opportunities to the risk of a magnitude 8 earthquake in China, here are five stories you may have missed over ...

(Reuters) -Danish drugmaker Novo Nordisk has secured the global rights to develop, manufacture and sell China-based United Laboratories International's weight-loss drug candidate in a deal worth up to ...

Danish drugmaker Novo Nordisk has bought global rights to China-based United Laboratories International's so-called "triple-G" weight-loss drug candidate in a deal worth up to $2 billion.

Obesity in girls rose to 7.7% in 2022 from 0.6% in 1990. “Obesity has become a major public health issue in China, ranking as the sixth leading risk factor for death and disability in the ...

Beijing (AsiaNews/Agencies) – China is stepping up efforts to counter the rise in obesity, placing scales in hotel rooms and promoting healthy recipes on social media. The initiative ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. China’s obesity crisis is a sizeable profit opportunity. More than half of Chinese adults are overweight ...

Novo will license UTB251, a triple hormone receptor agonist that in mid-2023 achieved 24% weight reduction at 48 weeks in a ...

Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by ...

AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker scrambles to revive business in its second-biggest market after scandals including ...